Lahmi A, Oryan S, Eidi A, Rohani A H
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Biological Science Faculty, Animal Physiology Department, Kharazmi University, Tehran,Iran.
Braz J Biol. 2023 Jan 6;84:e268781. doi: 10.1590/1519-6984.268781. eCollection 2023.
Following the obesity epidemics, nonalcoholic fatty liver disease (NAFLD) has grown in prevalence and become a main cause of morbidity and death, intimately linked to cardiovascular disease, cancer, and cirrhosis. The key factor in the evolution of NAFLD is thought to be oxidative stress. Because most patients cannot change their lifestyle or dietary habits, a pharmaceutical strategy is now required to treat NAFLD. Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis, is treated with vitamin E. (NASH). Vitamin E is also a powerful antioxidant that has been demonstrated to lower oxidative stress in people with NAFLD. Thymol is a monoterpene phenol with a variety of pharmacological effects, however its anti-fatty liver properties have yet to be investigated. Despite the fact that oxidative stress is thought to have a role in the etiology of nonalcoholic steatohepatitis, antioxidant therapies have not been well studied in the treatment of nonalcoholic steatohepatitis. The goal was to learn more about vitamin E and thymol's biological activities, with a particular emphasis on their therapeutic effectiveness in NAFLD. Four groups of thirty-two adult male rats were formed (healthy control, thymol, Vit E, and fatty liver). For 28 days, rats were given either oral vitamin E (200 mg/kg) or thymol (50 mg/kg) randomly. The levels of ALT, AST, TNF- α, Ferritin, CK-MB enzymes, and MAPK gene expression were then determined in the serum. Based on a random effect model analysis, at the end of 28 days of therapy, ALT (41.43 U/L), AST (47.91 U/L), Ferritin (1.13 pg/dl), CK-MB (251.22 IU/L), TNF-α (95.39 pg/mL) (p≤0.001), and MAPK gene expression levels (p≤0.05) significantly reduced in both experimental groups compared with the fatty liver group. Vitamin E and thymol therapy is a safe, affordable, and effective therapeutic option in the fatty liver group. Patients with fatty liver disease should be encouraged to take vitamin E and Thymol supplements, which are both safe and affordable, because more effective new therapeutic options are lacking.
随着肥胖症的流行,非酒精性脂肪性肝病(NAFLD)的患病率不断上升,已成为发病和死亡的主要原因,与心血管疾病、癌症和肝硬化密切相关。NAFLD进展的关键因素被认为是氧化应激。由于大多数患者无法改变他们的生活方式或饮食习惯,现在需要一种药物策略来治疗NAFLD。非酒精性脂肪性肝病(NAFLD),包括非酒精性脂肪性肝炎(NASH),可用维生素E进行治疗。维生素E也是一种强大的抗氧化剂,已被证明可以降低NAFLD患者的氧化应激。百里香酚是一种具有多种药理作用的单萜酚,但其抗脂肪肝特性尚未得到研究。尽管氧化应激被认为在非酒精性脂肪性肝炎的病因中起作用,但抗氧化疗法在非酒精性脂肪性肝炎的治疗中尚未得到充分研究。目的是更多地了解维生素E和百里香酚的生物学活性,特别关注它们在NAFLD中的治疗效果。将32只成年雄性大鼠分成四组(健康对照组、百里香酚组、维生素E组和脂肪肝组)。大鼠被随机给予口服维生素E(200mg/kg)或百里香酚(50mg/kg),持续28天。然后测定血清中ALT、AST、TNF-α、铁蛋白、CK-MB酶和MAPK基因表达水平。基于随机效应模型分析,在治疗28天结束时,与脂肪肝组相比,两个实验组的ALT(41.43U/L)、AST(|47.91U/L)、铁蛋白(1.13pg/dl)、CK-MB(251.22IU/L)、TNF-α(95.39pg/mL)(p≤0.001)和MAPK基因表达水平(p≤0.05)均显著降低。维生素E和百里香酚治疗在脂肪肝组中是一种安全、经济且有效的治疗选择。由于缺乏更有效的新治疗选择,应鼓励脂肪肝疾病患者服用既安全又经济的维生素E和百里香酚补充剂。